Last update 01 Nov 2024

Ancitabine Hydrochloride

Last update 01 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ancitabine hydrochloride (JAN)

Target

DNA polymerase

Mechanism

DNA polymerase inhibitors(DNA polymerase inhibitors)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC9H12ClN3O4

InChIKeyKZOWNALBTMILAP-JBMRGDGGSA-N

CAS Registry10212-25-6

100 Clinical Results associated with Ancitabine Hydrochloride

100 Translational Medicine associated with Ancitabine Hydrochloride

100 Patents (Medical) associated with Ancitabine Hydrochloride

Literatures (Medical) associated with Ancitabine Hydrochloride

01 Jan 2002·Clinical PharmacokineticsQ2 · MEDICINE

Clinical Pharmacokinetics of Cytarabine Formulations

Q2 · MEDICINE

Review

Author: Takeo Kawaguchi ; Akinobu Hamada ; Masahiro Nakano

Cytarabine (cytosine arabinoside, Ara-C) is an effective chemotherapeutic agent for the treatment of acute myelogenous leukaemia and lymphocytic leukaemias. As cytarabine is an S-phase-specific drug, prolonged exposure of cells to cytotoxic concentrations is critical to achieve maximum cytotoxic activity. However, the activity of cytarabine is decreased by its rapid deamination to the biologically inactive metabolite uracil arabinoside. This rapid deamination is the reason for the ongoing search for effective formulations and derivatives of cytarabine that cannot be deaminated and exhibit better pharmacokinetic parameters. Protection of cytarabine from fast degradation and elimination has been investigated by encapsulating the drug into pharmaceutically acceptable carriers. Cytarabine derivatives have shown promise in vitro and in animal models. For example, ancitabine (cyclocytidine), enocitabine and cytarabine ocfosfate have been used clinically in Japan. Cytarabine encapsulated into multivesicular liposomes has been approved in several countries for the intrathecal treatment of lymphomatous meningitis. Although many compounds have been investigated, few cytarabine derivatives are currently available for clinical use. Further research is needed to improve the efficacy of cytarabine against haematological and solid tumours.

01 Jun 1990·Journal of Medical VirologyQ4 · MEDICINE

Antiviral effect of antileukemic drugs N⁴‐Behenoyl‐1‐β‐D‐Arabinofuranosylcytosine (BH‐AC) and 2,2′‐Anhydro‐1‐β‐D‐Arabinofuranosylcytosine (Cyclo‐C) Against Human Cytomegalovirus

Q4 · MEDICINE

Article

Author: Yoshito Eizuru ; Yoichi Minamishima ; Kazuo Nakamura ; Keiko Kumura

AbstractThe antiviral activities of antileukemic drugs 1‐β‐D‐arabinofuranosylcytosine (Cytarabine; Ara‐C), 2,2′‐anhydro‐1‐β‐D‐arabinofuranosylcytosine (Ancitabine; Cyclo‐C), and N4‐behenoyl‐1‐β‐D‐arabinofuranosylcytosine (Enocitabine; BH‐AC) were evaluated in vitro against human cytomegalovirus (HCMV) in comparison with those of five other antiviral drugs. Both Ara‐C and Cyclo‐C showed the strongest inhibitory effect to HCMV. BH‐AC inhibited the replication of HCMV and depicted almost as the same dose‐response curve as Ganciclovir (DHPG). In the presence of Ara‐C, Cyclo‐C, or BH‐AC, triphosphate forms of the nucleoside analogs were detected in the HCMV‐infected cells, and synthesis of HCMV DNA was strongly suppressed. Thus, Ara‐C, Cyclo‐C, and BH‐AC were not only antileukemic, but also antiviral in vitro. However, Ara‐C and Cyclo‐C may not be suitable as anti‐HCMV agents, because they are cytotoxic or excreted rapidly in the urine in vivo [Van Voris, 1984; Hirayama et al., 1974]. Because of lower toxicity and longer retention in vivo, BH‐AC may be expected as an anti‐HCMV agent in patients with leukemia, in addition to serving as an antileukemic drug.

01 Oct 1987·Gan to kagaku ryoho. Cancer & chemotherapy

[Cytarabine].

Article

Author: Ota, K

Cytarabine (ara-C) is the first line agent with its excellent activity for acute myelogenous leukemia. Combination therapy of MFC (mitomycin C, 5-FU, ara-C) has been used for GI tract cancer with a synergistic effect on L-1210 mouse leukemia. In the results of research on the administration, a high dose ara-C is an effective agent in the refractory cases to the standard dose ara-C and the combination with daunorubicin is applied to a remission consolidation therapy. A small dose ara-C is used against an atypical leukemia with its mechanism of induction of differenciation. On the other hand, in the development of its derivertive compounds ancitabine or enocitabine (BH-AC) were induced to a treatment of acute myelogenous leukemia. Especially BH-AC is the first choice agent for acute myelogenous leukemia combined with other agents.

100 Deals associated with Ancitabine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01651	-	-	-

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis